Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Gilteritinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 known ✓ | P36888 | 14/20 | 0.87 |
| ▸ | AXL known ✓ | P30530 | 2/20 | 0.87 |
| ▸ | RET | P07949 | 12/20 | 0.87 |
| ▸ | ROS1 | P08922 | 12/20 | 0.87 |
| ▸ | EML4 | Q9HC35 | 12/20 | 0.87 |
| ▸ | ALK | Q9UM73 | 12/20 | 0.87 |
| ▸ | ETV6 | P41212 | 2/20 | 0.87 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.87 |
| ▸ | PLK4 | O00444 | 1/20 | 0.87 |
| ▸ | CIT | O14578 | 1/20 | 0.87 |
| ▸ | AURKA | O14965 | 1/20 | 0.87 |
| ▸ | GAK | O14976 | 1/20 | 0.87 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.87 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.87 |
| ▸ | BUB1 | O43683 | 1/20 | 0.87 |
| ▸ | SNRNP200 | O75643 | 1/20 | 0.87 |
| ▸ | STK16 | O75716 | 1/20 | 0.87 |
| ▸ | STK10 | O94804 | 1/20 | 0.87 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.87 |
| ▸ | LATS1 | O95835 | 1/20 | 0.87 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gilteritinib SCHEMBL22684906 | 0.97 | FLT3 (0.81) | FLT3RETROS1EML4ALK | |
| Gilteritinib SCHEMBL22684911 | 0.97 | FLT3 (0.81) | FLT3RETROS1EML4ALK | |
| Gilteritinib SCHEMBL282229 | 0.93 | FLT3 (1.00) | FLT3RETROS1EML4ALK | |
| Gilteritinib SCHEMBL29432551 | 0.93 | FLT3 (1.00) | FLT3RETROS1EML4ALK | |
| Gilteritinib SCHEMBL29355822 | 0.93 | FLT3 (1.00) | FLT3RETROS1EML4ALK | |
| Gilteritinib SCHEMBL22684910 | 0.91 | FLT3 (0.91) | FLT3RETROS1EML4ALK | |
| Gilteritinib SCHEMBL22684912 | 0.91 | FLT3 (0.91) | FLT3RETROS1EML4ALK | |
| SCHEMBL22694087 | 0.91 | FLT3 (0.87) | FLT3RETROS1EML4ALK | |
| SCHEMBL328303 | 0.90 | FLT3 (0.94) | FLT3RETROS1EML4ALK | |
| Gilteritinib SCHEMBL21819929 | 0.89 | FLT3 (1.00) | FLT3RETROS1EML4ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12264151-B2 | Substituted diamino heterocyclic carboxamide compound and a composition containing the compound and use thereof | SHENZHEN TARGETRX, INC. (CN) | 2025-04-01 | — | — | US | disclosed |
| US-20230138863-A1 | SUBSTITUTED DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND AND A COMPOSITION CONTAINING THE COMPOUND AND USE THEREOF | SHENZHEN TARGETRX, INC. (CN) | 2023-05-04 | — | — | US | disclosed |
| US-11512074-B2 | Substituted diamino heterocyclic carboxamide compound and a composition containing the compound and use thereof | SHENZHEN TARGETRX, INC. (CN) | 2022-11-29 | — | — | US | disclosed |
| US-20210094939-A1 | SUBSTITUTED DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND AND A COMPOSITION CONTAINING THE COMPOUND AND USE THEREOF | SHENZEN TARGETRX, INC. (CN) | 2021-04-01 | — | — | US | disclosed |
| EP-3741753-A1 | SUBSTITUTED DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND AND A COMPOSITION CONTAINING THE COMPOUND AND USE THEREOF | Shenzhen TargetRx, Inc. (CN) | 2020-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230138863-A1 | SUBSTITUTED DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND AND A COMPOSITION CONTAINING THE COMPOUND AND USE THEREOF | FLT3, AXL, ABL1 | FLT3 1/4885AXL 2/4885RET 6/4885 |
| US-12264151-B2 | Substituted diamino heterocyclic carboxamide compound and a composition containing the compound and use thereof | FLT3, AXL, ABL1 | FLT3 1/4885AXL 2/4885RET 6/4885 |
| US-11512074-B2 | Substituted diamino heterocyclic carboxamide compound and a composition containing the compound and use thereof | FLT3, AXL, ABL1 | FLT3 1/4885AXL 2/4885RET 6/4885 |
| US-20210094939-A1 | SUBSTITUTED DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND AND A COMPOSITION CONTAINING THE COMPOUND AND USE THEREOF | FLT3, AXL, ABL1 | FLT3 1/4885AXL 2/4885RET 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.